LT
|
SDD [81–85]
|
Reducing the high incidence of infection [81]
|
Human study
|
Gram-positive microorganisms infection predominated over Gram-negative rods and anaerobes [82]
|
Human study
|
No infection prevention [83–85]
|
Human study
|
Antibiotics [57]
|
Partly ameliorating enhanced ischemia/reperfusion injury
|
Animal study
|
LAB and fibers [87]
|
Reducing bacterial infection rates
|
Human study
|
Only fibers [87]
|
Reducing incidence of severe infections
|
Human study
|
Probiobics [88, 89]
|
Promoting partial restoration of intestinal microflora and improving intestinal barrier function [88]
|
Animal study
|
Reducing the liver injury by acute rejection [89]
|
Animal study
|
SBT
|
Probiotics [90]
|
Ameliorating small bowel histological injuries and reducing BT
|
Animal study
|
HSCT
|
TGID [86]
|
Preventing acute GVHD
|
Human study
|
Polymyxin B [70]
|
Ameliorating GVHD
|
Animal study
|
Probiotics [91]
|
Reduceing acute GVHD and improving survival
|
Animal study
|